{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T11:06:00Z","timestamp":1793531160863,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jcf.2025.07.008","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T03:08:30Z","timestamp":1753931310000},"page":"1043-1050","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Results of a clinical trial of ANG003, a non-porcine pancreatic enzyme replacement therapy, in people with cystic fibrosis"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7088-8530","authenticated-orcid":false,"given":"Meghana","family":"Sathe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7655-8954","authenticated-orcid":false,"given":"Melissa S.","family":"Putman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Gallotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcie","family":"Clarkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4930-7646","authenticated-orcid":false,"given":"Danielle","family":"Gallotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kateryna","family":"Pierzynowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3685-4078","authenticated-orcid":false,"given":"Drucy","family":"Borowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2025.07.008_bib0001","first-page":"261","article-title":"Gastric inactivation of pancreatic supplements","volume":"116","author":"Heizer","year":"1965","journal-title":"Bull Johns Hopkins Hosp"},{"issue":"4","key":"10.1016\/j.jcf.2025.07.008_bib0002","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1089\/ped.2010.0050","article-title":"Pancreatic Enzyme Products","volume":"23","author":"Hendeles","year":"2010","journal-title":"Pediatr Allergy Immunol Pulmonol"},{"key":"10.1016\/j.jcf.2025.07.008_bib0003","doi-asserted-by":"crossref","DOI":"10.1097\/MPA.0000000000002016","article-title":"Coefficient of fat absorption to measure the efficacy of pancreatic enzyme replacement therapy in people with cystic fibrosis: gold standard or coal standard?","author":"Borowitz","year":"2022","journal-title":"Pancreas"},{"issue":"4","key":"10.1016\/j.jcf.2025.07.008_bib0004","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1021\/mp4006529","article-title":"Characterization of a novel cross-linked lipase: impact of cross-linking on solubility and release from drug product","volume":"11","author":"Hetrick","year":"2014","journal-title":"Mol Pharm"},{"issue":"6","key":"10.1016\/j.jcf.2025.07.008_bib0005","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1056\/NEJMoa021218","article-title":"Association of cystic fibrosis with abnormalities in fatty acid metabolism","volume":"350","author":"Freedman","year":"2004","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jcf.2025.07.008_bib0006","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/MPG.0b013e3182618f33","article-title":"Relation between dietary fat intake type and serum fatty acid status in children with cystic fibrosis","volume":"55","author":"Maqbool","year":"2012","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"5","key":"10.1016\/j.jcf.2025.07.008_bib0007","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0284651","article-title":"Validation of an omega-3 substrate challenge absorption test as an indicator of global fat lipolysis","volume":"18","author":"Freedman","year":"2023","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jcf.2025.07.008_bib0008","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jcf.2011.07.001","article-title":"International phase III trial of liprotamase efficacy and safety in pancreatic-insufficient cystic fibrosis patients","volume":"10","author":"Borowitz","year":"2011","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2025.07.008_bib0009","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/MPG.0b013e31823315d1","article-title":"Liprotamase long-term safety and support of nutritional status in pancreatic-insufficient cystic fibrosis","volume":"54","author":"Borowitz","year":"2012","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"1","key":"10.1016\/j.jcf.2025.07.008_bib0010","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/MPG.0000000000001617","article-title":"Increased fat absorption from enteral formula through an In-line digestive cartridge in patients with cystic fibrosis","volume":"65","author":"Freedman","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"4","key":"10.1016\/j.jcf.2025.07.008_bib0011","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/MPG.0000000000002110","article-title":"Absorption and safety with sustained use of RELiZORB evaluation (ASSURE) study in patients with cystic fibrosis receiving enteral feeding","volume":"67","author":"Stevens","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"1","key":"10.1016\/j.jcf.2025.07.008_bib0012","doi-asserted-by":"crossref","first-page":"bpae078","DOI":"10.1093\/biomethods\/bpae078","article-title":"Modified throughput ninhydrin method for the qualitative assessment of dietary protein absorption in pig plasma","volume":"9","author":"Pierzynowska","year":"2024","journal-title":"Biol Methods Protoc"},{"key":"10.1016\/j.jcf.2025.07.008_bib0013","unstructured":"Cystic Fibrosis Foundation Patient Registry Patient Registry 2023 annual Data report. 2023."},{"issue":"5","key":"10.1016\/j.jcf.2025.07.008_bib0014","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00228-008-0605-4","article-title":"Relative bioavailability and pharmacokinetics of two oral formulations of docosahexaenoic acid\/eicosapentaenoic acid after multiple-dose administration in healthy volunteers","volume":"65","author":"Rusca","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jcf.2025.07.008_bib0015","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1476-511X-12-102","article-title":"Acute appearance of fatty acids in human plasma\u2013a comparative study between polar-lipid rich oil from the microalgae Nannochloropsis oculata and krill oil in healthy young males","volume":"12","author":"Kagan","year":"2013","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.jcf.2025.07.008_bib0016","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1475-2891-6-4","article-title":"A randomised cross-over trial in healthy adults indicating improved absorption of omega-3 fatty acids by pre-emulsification","volume":"6","author":"Garaiova","year":"2007","journal-title":"Nutr J"},{"issue":"2","key":"10.1016\/j.jcf.2025.07.008_bib0017","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1079\/BJN20051655","article-title":"Serum phospholipid fatty acid profile and dietary intake in an adult Mediterranean population with cystic fibrosis","volume":"96","author":"Olveira","year":"2006","journal-title":"Br J Nutr"},{"issue":"6","key":"10.1016\/j.jcf.2025.07.008_bib0018","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jacl.2012.01.002","article-title":"A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(R) compared to Lovaza(R) in a pharmacokinetic single-dose evaluation) study","volume":"6","author":"Davidson","year":"2012","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jcf.2025.07.008_bib0019","article-title":"Recent studies confirm the utility of the omega-3 index","author":"Harris","year":"2024","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"4","key":"10.1016\/j.jcf.2025.07.008_bib0020","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/ncp.11142","article-title":"Association of in-line digestive enzyme cartridge with enteral feeds on improvement in anthropometrics among pediatric patients with cystic fibrosis","volume":"39","author":"Shrivastava","year":"2024","journal-title":"Nutr Clin Pract"},{"issue":"5\u20136","key":"10.1016\/j.jcf.2025.07.008_bib0021","first-page":"309","article-title":"Fatty acid alterations and n-3 fatty acid supplementation in cystic fibrosis","volume":"77","author":"MR","year":"2007","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"issue":"9","key":"10.1016\/j.jcf.2025.07.008_bib0022","doi-asserted-by":"crossref","DOI":"10.3390\/nu12092555","article-title":"Expert opinion on benefits of long-chain omega-3 fatty acids (DHA and EPA) in aging and clinical nutrition","volume":"12","author":"Troesch","year":"2020","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.jcf.2025.07.008_bib0023","article-title":"Omega-3 fatty acids for cystic fibrosis","volume":"2016","author":"Oliver","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.jcf.2025.07.008_bib0024","doi-asserted-by":"crossref","DOI":"10.3390\/nu16070970","article-title":"Impact of 1-year supplementation with high-rich docosahexaenoic acid (DHA) on clinical variables and inflammatory biomarkers in pediatric cystic fibrosis: a randomized double-blind controlled trial","volume":"16","author":"Ayats-Vidal","year":"2024","journal-title":"Nutrients"},{"issue":"8","key":"10.1016\/j.jcf.2025.07.008_bib0025","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1136\/gut.52.8.1159","article-title":"Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas","volume":"52","author":"Ahmed","year":"2003","journal-title":"Gut"},{"issue":"Suppl 6","key":"10.1016\/j.jcf.2025.07.008_bib0026","doi-asserted-by":"crossref","first-page":"vi1","DOI":"10.1136\/gut.2005.065946","article-title":"Human pancreatic exocrine response to nutrients in health and disease","volume":"54","author":"Keller","year":"2005","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.jcf.2025.07.008_bib0027","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/ajcn\/20.1.24","article-title":"The kinetics of amino acid absorption and alteration of plasma composition of free amino acids after intestinal perfusion of amino acid mixtures","volume":"20","author":"Adibi","year":"1967","journal-title":"Am J Clin Nutr"},{"issue":"6","key":"10.1016\/j.jcf.2025.07.008_bib0028","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.clnu.2013.11.004","article-title":"New stable isotope method to measure protein digestibility and response to pancreatic enzyme intake in cystic fibrosis","volume":"33","author":"Engelen","year":"2014","journal-title":"Clin Nutr"},{"issue":"5","key":"10.1016\/j.jcf.2025.07.008_bib0029","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0323730","article-title":"Validation of dietary whey protein substrate challenge absorption test as an indicator of proteolysis","volume":"20","author":"Pierzynowska","year":"2025","journal-title":"PLoS One"}],"updated-by":[{"DOI":"10.1016\/j.jcf.2025.11.017","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000}},{"DOI":"10.1016\/j.jcf.2025.11.017","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000}}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325015292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325015292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:35:26Z","timestamp":1779953726000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325015292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1569199325015292"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.07.008","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Results of a clinical trial of ANG003, a non-porcine pancreatic enzyme replacement therapy, in people with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}